Experienced in Necrotizing Fasciitis

Mindaugas Jievaltas

A. Mickeviciaus Str. 9, 
Kaunas, KU, LT 
Experienced in Necrotizing Fasciitis
A. Mickeviciaus Str. 9, 
Kaunas, KU, LT 
OverviewLocationsClinical Research

Overview

Mindaugas Jievaltas practices in Kaunas, Lithuania. Jievaltas is rated as an Experienced expert by MediFind in the treatment of Necrotizing Fasciitis. Their top areas of expertise are Prostate Cancer, Gangrene, Necrotizing Fasciitis, Prostatectomy, and Nephrectomy.

Their clinical research consists of co-authoring 45 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Necrotizing Fasciitis.

Locations

A. Mickeviciaus Str. 9, Kaunas, KU LT44307, Lithuania
Other Locations
Eiveniu Str. 4, Kaunas, KU LT50161, Lithuania

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).
A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).
Enrollment Status: Completed
Publish Date: December 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer
Enrollment Status: Completed
Publish Date: May 04, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

45 Total Publications

Rare and Aggressive Disease: Urinary Bladder Leiomyosarcoma.
Rare and Aggressive Disease: Urinary Bladder Leiomyosarcoma.
Journal: Journal of clinical medicine
Published: June 27, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Jievaltas's expertise for a condition
ConditionClose
      View All 8 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile